Title:
HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/138583
Kind Code:
A1
Abstract:
Provided in the present invention are a heterocyclic compound, a pharmaceutical composition and the use thereof. Specifically disclosed are a heterocyclic compound as represented by formula (I-0), a pharmaceutically acceptable salt or stereoisomer of the heterocyclic compound, or a solvate thereof. The compound of the present invention has a novel structure and relatively good activity and selectivity.
Inventors:
XIAO YISONG (CN)
GU XIAOHUI (CN)
LAI KUNMIN (CN)
GU XIAOHUI (CN)
LAI KUNMIN (CN)
Application Number:
PCT/CN2023/072654
Publication Date:
July 27, 2023
Filing Date:
January 17, 2023
Export Citation:
Assignee:
SHANGHAI APEIRON THERAPEUTICS COMPANY LTD (CN)
International Classes:
C07D519/00; A61K31/407; A61K31/517; A61K31/519; A61P35/00; C07D239/72; C07D239/94; C07D401/14; C07D403/04; C07D403/14; C07D413/14; C07D471/04; C07D471/08; C07D487/08
Domestic Patent References:
| WO2022015375A1 | 2022-01-20 | |||
| WO2022042630A1 | 2022-03-03 | |||
| WO2022061251A1 | 2022-03-24 | |||
| WO2022002102A1 | 2022-01-06 | |||
| WO2022132200A1 | 2022-06-23 | |||
| WO2021041671A1 | 2021-03-04 | |||
| WO2020146613A1 | 2020-07-16 | |||
| WO2022214102A1 | 2022-10-13 | |||
| WO2022068921A1 | 2022-04-07 | |||
| WO2022105859A1 | 2022-05-27 | |||
| WO2022148422A1 | 2022-07-14 | |||
| WO2022170999A1 | 2022-08-18 | |||
| WO2022171147A1 | 2022-08-18 | |||
| WO2022173870A1 | 2022-08-18 | |||
| WO2022177917A2 | 2022-08-25 | |||
| WO2022184178A1 | 2022-09-09 | |||
| WO2022187528A1 | 2022-09-09 | |||
| WO2022192794A1 | 2022-09-15 | |||
| WO2022194191A1 | 2022-09-22 | |||
| WO2022228543A1 | 2022-11-03 | |||
| WO2022228568A1 | 2022-11-03 | |||
| WO2022232331A1 | 2022-11-03 | |||
| WO2022232332A1 | 2022-11-03 | |||
| WO2022236578A1 | 2022-11-17 | |||
| WO2022247760A1 | 2022-12-01 | |||
| WO2022248885A2 | 2022-12-01 | |||
| WO2022258974A1 | 2022-12-15 | |||
| WO2022262686A1 | 2022-12-22 | |||
| WO2023274324A1 | 2023-01-05 | |||
| WO2023280280A1 | 2023-01-12 | |||
| WO2022221739A1 | 2022-10-20 |
Foreign References:
| CN115141215A | 2022-10-04 | |||
| CN115197245A | 2022-10-18 | |||
| CN115304623A | 2022-11-08 | |||
| CN115490709A | 2022-12-20 |
Other References:
WANG XIAOLUN, ALLEN SHELLEY, BLAKE JAMES F., BOWCUT VICKIE, BRIERE DAVID M., CALINISAN ANDREW, DAHLKE JOSHUA R., FELL JAY B., FISC: "Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 65, no. 4, 24 February 2022 (2022-02-24), US , pages 3123 - 3133, XP055952002, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.1c01688
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: